Insights

  • Date

  • Content Type

  • Reset

Blog

Enabling Access Through Innovation – Cell and Gene Therapy in 2023 and Beyond

16.01.23
Dr. Jörg Schneider, Director – Principal Consultant at BioPharma Excellence, previews the opening plenary session
Read More

Blog

The next breakthrough: using Cell Therapies to treat solid tumors

1.01.23

By Cori Gorman, Ph.D.

Cell therapy has advanced both in the clinic and in drug approvals. Research is focused on two approaches to...
Read More

Article

Why Regulatory Convergence is Key to Global Development of Cell and Gene Therapies

20.12.22

By Francesco Lanucara

There is growing excitement about the potential shown by cell and gene therapies, particularly in
Read More

Article

Managing the Complex Regulatory Pathways for Bioprinting Breakthroughs

20.12.22

By Elena Meurer and Mariya Gromova

Bioprinted products are already starting to demonstrate life-changing potential, but the path to commercialisation is
Read More

Blog

What a year! Biopharma Excellence has been easing the path to market for a whole host of advanced therapies and biosimilars

28.11.22
by Dr. Christian K Schneider Head of Biopharma Excellence   As Biopharma Excellence marks its
Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more